Vimarsana
Biggest News Aggregation in the World

Page 40 - Shannon Devine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Shannon Devine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Shannon Devine Today - Breaking & Trending Today

Tenon Medical, Inc.: Tenon Medical Announces Treatment of First Patient in Strategic Post Market Clinical Study with Company's Catamaran SI Joint Fusion System - Vimarsana News

Tenon Medical, Inc.: Tenon Medical Announces Treatment of First Patient in Strategic Post Market Clinical Study with Company's Catamaran SI Joint Fusion System

Mark H. Stouffer, MD and team from Zion Surgery Center perform first case in St George, UT.This clinical study will assess patient pain scores, fusion as well as other patient reported outcomes out to

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614 - Vimarsana News

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces FDA Guidance on the Clinical Development Pathway for PF614

~ Acute pain indication may be appropriate, with potential to significantly shorten development path ~SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company")

Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Third Quarter 2022 Financial Results - Vimarsana News

Ensysce Biosciences, Inc.: Ensysce Biosciences Reports Third Quarter 2022 Financial Results

Corporate Update Call to be Held Wednesday, November 16, 2022SAN DIEGO, CA / ACCESSWIRE / November 14, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage

Tenon Medical, Inc. Announces Participation in Upcoming Conferences - Vimarsana News

Tenon Medical, Inc. Announces Participation in Upcoming Conferences

LOS GATOS, CA / ACCESSWIRE / November 2, 2022 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon Medical" or the "Company"), a company transforming care for patients suffering with certain sacroiliac disorders

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product - Vimarsana News

Ensysce Biosciences, Inc.: Ensysce Biosciences Announces Positive Topline Results of Clinical Study Evaluating Human Abuse Potential of Intranasal Administration of PF614, a TAAP Abuse-Deterrent Oxycodone Extended-Release Product

~ Announces Timing of Corporate Update Call ~SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech